PDCD1LG2 and melanoma: Collectively, our study demonstrates that PD‐L2+ EVs inhibit CD8 T cell activation and promote melanoma growth, and changes in PD‐L2 on circulating EVs during early treatment could serve as a biomarker for ICI‐based therapy.